Table 1.
Cox proportional hazards analyses of the association between PFS and OS and the classification of the clinical cohorts for doxorubcin REGS developed using HBCCL or CGP cell line panels
| HBCCL | CGP | |||||
|---|---|---|---|---|---|---|
| N | HR (95% CI) | P-value | N | HR (95% CI) | P-value | |
| REGS classifier (univariate) | ||||||
| IDRC (PFS) | 470 | 2.58 (1.72,3.86) | 4.37E-06 | 470 | 1.54 (1.07,2.22) | 0.0211 |
| LLMPP (PFS) | 220 | 2.28 (1.10,4.73) | 0.0269 | 220 | 1.70 (0.89,3.22) | 0.105 |
| MDFCI (OS) | 67 | 4.56 (1.29,16.19) | 0.0188 | 67 | 0.93 (0.28,3.04) | 0.899 |
| REGS classifier (adjusted for IPI) | ||||||
| IDRC (PFS) | 424 | 2.52 (1.64,3.87) | 2.65E-05 | 424 | 1.46 (0.99,2.16) | 0.0562 |
| LLMPP (PFS) | 180 | 2.52 (1.13,5.64) | 0.0237 | 180 | 1.37 (0.68,2.74) | 0.375 |
| MDFCI (OS) | 63 | 4.05 (1.13,14.51) | 0.0318 | 63 | 0.84 (0.25,2.76) | 0.769 |
| REGS predictor (univariate) | ||||||
| IDRC (PFS) | 470 | 1.11 (1.04,1.17) | 0.000572 | 470 | 1.07 (1.01,1.13) | 0.0131 |
| LLMPP (PFS) | 220 | 1.10 (1.00,1.20) | 0.0438 | 220 | 1.09 (0.99,1.19) | 0.0794 |
| MDFCI (OS) | 67 | 1.32 (1.14,1.54) | 0.000318 | 67 | 0.96 (0.83,1.12) | 0.63 |
| REGS predictor (adjusted for IPI) | ||||||
| IDRC (PFS) | 424 | 1.09 (1.03,1.16) | 0.00595 | 424 | 1.05 (1.00,1.11) | 0.0733 |
| LLMPP (PFS) | 180 | 1.11 (1.00,1.23) | 0.0433 | 180 | 1.04 (0.94,1.15) | 0.467 |
| MDFCI (OS) | 63 | 1.34 (1.15,1.57) | 0.000237 | 63 | 0.95 (0.83,1.07) | 0.387 |
In the multivariate analysis the Cox proportional hazards regression is adjusted for IPI. The estimated HR’s compare patients classified as resistant to patients classified as sensitive.